Junyu Chen, Xiaoxue Fu, Aisha S Ahmed, David A Hart, Zongke Zhou, Paul W Ackermann
{"title":"人类结缔组织修复和愈合结果相关生物标志物的系统综述:对理解愈合过程和愈合干预设计的意义。","authors":"Junyu Chen, Xiaoxue Fu, Aisha S Ahmed, David A Hart, Zongke Zhou, Paul W Ackermann","doi":"10.1089/wound.2024.0233","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> The healing process following connective tissue (CT) injuries is complex, resulting in variable and often suboptimal outcomes. Patients undergoing CT repair frequently experience healing failures, compromised function, and chronic degenerative diseases. The identification of biomarkers to guide improved clinical outcomes after CT injuries remains an emerging but promising field. [Figure: see text] [Figure: see text] <b>Design:</b> Systematic review. <b>Data sources:</b> Databases, including PubMed, MEDLINE Ovid, Web of Science, and Google Scholar, were searched up to August 2024. <b>Eligibility criteria:</b> To achieve the research objective, randomized control trials, cohort studies, and case-control studies on biomarkers associated with CT repair and healing outcomes were selected. The present analysis was confined to clinical and preclinical models, excluding imaging studies. The entire process of this systematic review adhered strictly to the guidelines outlined in the Preferred Reporting Items for Systematic Review and Meta-Analyses protocol checklist. <b>Results:</b> A total of 1,815 studies on biomarkers of CT repair were initially identified, with 75 studies meeting eligibility criteria and 55 passing quality assessments. For biomarkers associated with CT healing outcomes, 281 studies were considered, with 30 studies meeting eligibility criteria and 24 passing quality assessments. Twenty-one overlapping studies investigated the effects of biomarkers on both CT repair and healing outcomes. Specific biomarkers identified, and ranked from highest to lowest quality, include complement factor D, eukaryotic elongation factor-2, procollagen type I N-terminal propetide, procollagen type III N-terminal propetide, lactate, pyruvate, platelet-derived growth factor-BB, tissue inhibitor of metalloproteinase-3 (TIMP-3), cysteine-rich protein-1, plastin-3, periostin, protein S100-A11, vimentin, matrix metalloproteinases (MMP-2, MMP-7, and MMP-9), hepatocyte growth factor, interferon-γ, interleukins (IL-6, IL-8, and IL-10), MMP-1, MMP-3, tumor necrosis factor-α, fibroblast growth factor-2, IL-1α, chondroitin-6-sulfate, inter-alpha-trypsin inhibitor heavy chain-4, transforming growth factor-beta 1, vascular endothelial growth factor, C-C chemokine receptor 7, C-C chemokine ligand 19, IL-1β, IL-1Ra, IL-12p40, granulocyte-macrophage colony-stimulating factor (GM-CSF), and TIMP-1. <b>Conclusions:</b> All of the 37 identified potential biomarkers demonstrated regulatory effects on CT repair and mediated healing outcomes. Notably, the identified biomarkers from human studies can potentially play an essential role in the development of targeted treatment protocols to counteract compromised healing and can also serve as predictors for detecting CT healing processes and long-term outcomes.</p>","PeriodicalId":7413,"journal":{"name":"Advances in wound care","volume":" ","pages":""},"PeriodicalIF":5.8000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Systematic Review of Relevant Biomarkers for Human Connective Tissue Repair and Healing Outcome: Implications for Understanding Healing Processes and Design of Healing Interventions.\",\"authors\":\"Junyu Chen, Xiaoxue Fu, Aisha S Ahmed, David A Hart, Zongke Zhou, Paul W Ackermann\",\"doi\":\"10.1089/wound.2024.0233\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> The healing process following connective tissue (CT) injuries is complex, resulting in variable and often suboptimal outcomes. Patients undergoing CT repair frequently experience healing failures, compromised function, and chronic degenerative diseases. The identification of biomarkers to guide improved clinical outcomes after CT injuries remains an emerging but promising field. [Figure: see text] [Figure: see text] <b>Design:</b> Systematic review. <b>Data sources:</b> Databases, including PubMed, MEDLINE Ovid, Web of Science, and Google Scholar, were searched up to August 2024. <b>Eligibility criteria:</b> To achieve the research objective, randomized control trials, cohort studies, and case-control studies on biomarkers associated with CT repair and healing outcomes were selected. The present analysis was confined to clinical and preclinical models, excluding imaging studies. The entire process of this systematic review adhered strictly to the guidelines outlined in the Preferred Reporting Items for Systematic Review and Meta-Analyses protocol checklist. <b>Results:</b> A total of 1,815 studies on biomarkers of CT repair were initially identified, with 75 studies meeting eligibility criteria and 55 passing quality assessments. For biomarkers associated with CT healing outcomes, 281 studies were considered, with 30 studies meeting eligibility criteria and 24 passing quality assessments. Twenty-one overlapping studies investigated the effects of biomarkers on both CT repair and healing outcomes. Specific biomarkers identified, and ranked from highest to lowest quality, include complement factor D, eukaryotic elongation factor-2, procollagen type I N-terminal propetide, procollagen type III N-terminal propetide, lactate, pyruvate, platelet-derived growth factor-BB, tissue inhibitor of metalloproteinase-3 (TIMP-3), cysteine-rich protein-1, plastin-3, periostin, protein S100-A11, vimentin, matrix metalloproteinases (MMP-2, MMP-7, and MMP-9), hepatocyte growth factor, interferon-γ, interleukins (IL-6, IL-8, and IL-10), MMP-1, MMP-3, tumor necrosis factor-α, fibroblast growth factor-2, IL-1α, chondroitin-6-sulfate, inter-alpha-trypsin inhibitor heavy chain-4, transforming growth factor-beta 1, vascular endothelial growth factor, C-C chemokine receptor 7, C-C chemokine ligand 19, IL-1β, IL-1Ra, IL-12p40, granulocyte-macrophage colony-stimulating factor (GM-CSF), and TIMP-1. <b>Conclusions:</b> All of the 37 identified potential biomarkers demonstrated regulatory effects on CT repair and mediated healing outcomes. Notably, the identified biomarkers from human studies can potentially play an essential role in the development of targeted treatment protocols to counteract compromised healing and can also serve as predictors for detecting CT healing processes and long-term outcomes.</p>\",\"PeriodicalId\":7413,\"journal\":{\"name\":\"Advances in wound care\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.8000,\"publicationDate\":\"2025-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in wound care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/wound.2024.0233\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in wound care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/wound.2024.0233","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:结缔组织(CT)损伤后的愈合过程是复杂的,导致不同的,往往是次优的结果。接受CT修复的患者经常经历愈合失败、功能受损和慢性退行性疾病。识别生物标记物来指导CT损伤后改善临床结果仍然是一个新兴但有前途的领域。[图:见文][图:见文]设计:系统评价。数据来源:检索截止到2024年8月的数据库,包括PubMed、MEDLINE Ovid、Web of Science和谷歌Scholar。入选标准:为了达到研究目的,选择了与CT修复和愈合结果相关的生物标志物的随机对照试验、队列研究和病例对照研究。目前的分析仅限于临床和临床前模型,不包括影像学研究。本系统评价的整个过程严格遵守系统评价和荟萃分析方案清单中列出的首选报告项目的指导方针。结果:初步确定了1,815项关于CT修复生物标志物的研究,其中75项研究符合资格标准,55项研究通过质量评估。对于与CT愈合结果相关的生物标志物,纳入了281项研究,其中30项研究符合资格标准,24项研究通过了质量评估。21项重叠研究调查了生物标志物对CT修复和愈合结果的影响。鉴定出的特异性生物标志物,质量从高到低排序包括补体因子D、真核延伸因子-2、I型前胶原n端肽、III型前胶原n端肽、乳酸、丙酮酸、血小板源性生长因子- bb、金属蛋白酶-3组织抑制剂(TIMP-3)、富含半胱氨酸的蛋白-1、plastin-3、骨膜蛋白、蛋白S100-A11、vimentin、基质金属蛋白酶(MMP-2、MMP-7和MMP-9)、肝细胞生长因子、干扰素-γ、白细胞介素(IL-6、IL-8和IL-10)、MMP-1、MMP-3、肿瘤坏死因子-α、成纤维细胞生长因子-2、IL-1α、硫酸软骨素-6、α -胰蛋白酶间抑制剂重链-4、转化生长因子- β 1、血管内皮生长因子、C-C趋化因子受体7、C-C趋化因子配体19、IL-1β、IL-1Ra、IL-12p40、粒细胞-巨噬细胞集落刺激因子(GM-CSF)和TIMP-1。结论:所有37个已确定的潜在生物标志物都对CT修复和介导的愈合结果具有调节作用。值得注意的是,从人类研究中鉴定出的生物标志物可能在开发靶向治疗方案中发挥重要作用,以抵消受损的愈合,也可以作为检测CT愈合过程和长期结果的预测因子。
Systematic Review of Relevant Biomarkers for Human Connective Tissue Repair and Healing Outcome: Implications for Understanding Healing Processes and Design of Healing Interventions.
Objective: The healing process following connective tissue (CT) injuries is complex, resulting in variable and often suboptimal outcomes. Patients undergoing CT repair frequently experience healing failures, compromised function, and chronic degenerative diseases. The identification of biomarkers to guide improved clinical outcomes after CT injuries remains an emerging but promising field. [Figure: see text] [Figure: see text] Design: Systematic review. Data sources: Databases, including PubMed, MEDLINE Ovid, Web of Science, and Google Scholar, were searched up to August 2024. Eligibility criteria: To achieve the research objective, randomized control trials, cohort studies, and case-control studies on biomarkers associated with CT repair and healing outcomes were selected. The present analysis was confined to clinical and preclinical models, excluding imaging studies. The entire process of this systematic review adhered strictly to the guidelines outlined in the Preferred Reporting Items for Systematic Review and Meta-Analyses protocol checklist. Results: A total of 1,815 studies on biomarkers of CT repair were initially identified, with 75 studies meeting eligibility criteria and 55 passing quality assessments. For biomarkers associated with CT healing outcomes, 281 studies were considered, with 30 studies meeting eligibility criteria and 24 passing quality assessments. Twenty-one overlapping studies investigated the effects of biomarkers on both CT repair and healing outcomes. Specific biomarkers identified, and ranked from highest to lowest quality, include complement factor D, eukaryotic elongation factor-2, procollagen type I N-terminal propetide, procollagen type III N-terminal propetide, lactate, pyruvate, platelet-derived growth factor-BB, tissue inhibitor of metalloproteinase-3 (TIMP-3), cysteine-rich protein-1, plastin-3, periostin, protein S100-A11, vimentin, matrix metalloproteinases (MMP-2, MMP-7, and MMP-9), hepatocyte growth factor, interferon-γ, interleukins (IL-6, IL-8, and IL-10), MMP-1, MMP-3, tumor necrosis factor-α, fibroblast growth factor-2, IL-1α, chondroitin-6-sulfate, inter-alpha-trypsin inhibitor heavy chain-4, transforming growth factor-beta 1, vascular endothelial growth factor, C-C chemokine receptor 7, C-C chemokine ligand 19, IL-1β, IL-1Ra, IL-12p40, granulocyte-macrophage colony-stimulating factor (GM-CSF), and TIMP-1. Conclusions: All of the 37 identified potential biomarkers demonstrated regulatory effects on CT repair and mediated healing outcomes. Notably, the identified biomarkers from human studies can potentially play an essential role in the development of targeted treatment protocols to counteract compromised healing and can also serve as predictors for detecting CT healing processes and long-term outcomes.
期刊介绍:
Advances in Wound Care rapidly shares research from bench to bedside, with wound care applications for burns, major trauma, blast injuries, surgery, and diabetic ulcers. The Journal provides a critical, peer-reviewed forum for the field of tissue injury and repair, with an emphasis on acute and chronic wounds.
Advances in Wound Care explores novel research approaches and practices to deliver the latest scientific discoveries and developments.
Advances in Wound Care coverage includes:
Skin bioengineering,
Skin and tissue regeneration,
Acute, chronic, and complex wounds,
Dressings,
Anti-scar strategies,
Inflammation,
Burns and healing,
Biofilm,
Oxygen and angiogenesis,
Critical limb ischemia,
Military wound care,
New devices and technologies.